On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard-of-care antihypertensives.  The company announced the topline results from the KARDIA-2 study in March 2024. When added to the standard of care, indapamide and, amlodipine, zilebesiran respectively achieved reductions of 12.1 mmHg (p<0.001) and 9.7 mmHg (p<0.001) in the primary endpoint of change from baseline in 24-hour mean systolic blood pressure at three months. However, when added to olmesartan, the experimental drug delivered a 4 mmHg reduction, missing statistical significance (p=0.036).  Similarly, when added to the standard of care, indapamide and, amlodipine, zilebesiran, respectively, achieved reductions of 11.0 mmHg ...